Journal article icon

Journal article

Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis.

Abstract:

BACKGROUND: Cyclophosphamide induction regimens for antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis are effective in 70 to 90% of patients, but they are associated with high rates of death and adverse events. Treatment with rituximab has led to remission rates of 80 to 90% among patients with refractory ANCA-associated vasculitis and may be safer than cyclophosphamide regimens. METHODS: We compared rituximab with cyclophosphamide as induction therapy in ANCA-associated vascu...

Expand abstract
Publication status:
Published

Actions


Access Document


Publisher copy:
10.1056/nejmoa0909169

Authors


More by this author
Institution:
University of Oxford
Department:
Oxford, MSD, NDORMS
Role:
Author
Expand authors...
Journal:
The New England journal of medicine
Volume:
363
Issue:
3
Pages:
211-220
Publication date:
2010-07-05
DOI:
EISSN:
1533-4406
ISSN:
0028-4793
URN:
uuid:d923d101-9b4b-42ce-ad30-82e1eb8dcaf7
Source identifiers:
108789
Local pid:
pubs:108789

Terms of use


Metrics


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP